Fasken

Fasken is a prominent Canadian law firm that was established in 1862 and is headquartered in Toronto. With over 700 lawyers and ten offices across four continents, Fasken offers a comprehensive range of legal services. Its practice areas encompass competition and marketing, corporate finance, corporate social responsibility, estate planning, government relations, indigenous law, and investment management. The firm serves a diverse clientele, providing legal expertise to sectors including cannabis, construction, energy, financial services, healthcare, infrastructure, insurance, life sciences, and real estate.

Peter Ascherl

Partner

Simon Bisson

Partner

Michel Boislard

Partner

Sylvie Bourdeau

Partner and Co-Leader, Life Sciences

Andrea Centa

Partner

Enoch Chang JD

Partner

Paul Fornazzari

Partner

John Grieve

Partner

Michael Hobkirk JD

Associate

Paul Khoury

Associate

Alexandra Lazar

Partner

Jay Lefton

Partner

Grant McGlaughlin

Partner and Co-leader of the Private Equity Group

Marie-Josee Neveu

Partner

Douglas New JD

Partner

Neil Smiley

Partner

Kadiatou Sow

Partner

Andre Turmel

Partner

Shanlee von Vegesack JD

Partner

Kareen Zimmer

Partner

2 past transactions

Pro Bono Ontario

Grant in 2019
Pro Bono Ontario (PBO) bridges the gap between lawyers who want to donate their services and low-income Ontarians who cannot afford a lawyer or qualify for legal aid.

Asmacure Ltée

Series A in 2007
Asmacure Ltée is a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of inflammation, notably pulmonary airway diseases. The company’s lead compound, ASM-024, has a novel multi-functional mechanism of action with nicotinic and muscarinic effects. ASM-024 has demonstrated the capabilities of anti-inflammation, bronchoprotection, and smooth muscle relaxation in pre-clinical asthma models. Administered as a solution for nebulization in asthma patients, ASM-024 demonstrated clinical proof of concept in a phase 2 trial with significant effects on FEV1 and methacholine PC20. Asmacure has advanced ASM-024 into the clinic for the treatment of moderate asthma and COPD with a dry powder for inhalation (DPI) formulation. The DPI is a preferred dosage form for many patients and should allow ASM-024 to be delivered with greater lung deposition yielding the potential for a lower and more optimal dose. Asmacure was founded by Dr. Yvon Cormier, a noted pulmonologist, and Dr Evelyne Israel-Assayag in 2002 and is based in Quebec City, Quebec, Canada.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.